Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
To evaluate, in patients with progressive neuroendocrine tumours who are not eligible to be
treated with either surgery or chemotherapy at the moment of study inclusion, the efficacy of
lanreotide Autogel in tumour growth stabilization.